Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
Fiche publication
Date publication
juin 2020
Journal
Cancer immunology, immunotherapy : CII
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe
Tous les auteurs :
Simonaggio A, Elaidi R, Fournier L, Fabre E, Ferrari V, Borchiellini D, Thouvenin J, Barthelemy P, Thibault C, Tartour E, Oudard S, Vano YA
Lien Pubmed
Résumé
An elevated pre-treatment neutrophil to lymphocytes ratio (NLR) is associated with poor prognosis in various malignancies. Optimal cut-off is highly variable across studies and could not be determined individually for a patient to inform his prognosis. We hypothesize that NLR variations could be more useful than baseline NLR to predict progression-free survival (PFS) and overall survival (OS) in patients (pts) receiving anti-PD1 treatment.
Mots clés
Anti-PD1, NLR variation, Neutrophil to lymphocyte ratio (NLR), Nivolumab, Non-small cell lung cancer, Renal cell carcinoma
Référence
Cancer Immunol. Immunother.. 2020 Jun 19;: